Source: Journal of endometriosis and pelvic pain disorders. Unidade: FM
Subjects: DISPAREUNIA, ENDOMETRIOSE, MENOPAUSA, CLIMATÉRIO, DOR, QUALIDADE DE VIDA, HORMÔNIO LIBERADOR DE GONADOTROFINAS
ABNT
LEYLAND, Nicholas et al. Elagolix reduced dyspareunia and improved health-related quality of life in premenopausal women with endometriosis-associated pain. Journal of endometriosis and pelvic pain disorders, v. 11, n. 4, p. 171-180, 2019Tradução . . Disponível em: https://doi.org/10.1177/2284026519872401. Acesso em: 20 ago. 2024.APA
Leyland, N., Taylor, H. S., Archer, D. F., Peloso, P. M., Soliman, A. M., Palac, H. L., et al. (2019). Elagolix reduced dyspareunia and improved health-related quality of life in premenopausal women with endometriosis-associated pain. Journal of endometriosis and pelvic pain disorders, 11( 4), 171-180. doi:10.1177/2284026519872401NLM
Leyland N, Taylor HS, Archer DF, Peloso PM, Soliman AM, Palac HL, Martinez M, Abrao MS. Elagolix reduced dyspareunia and improved health-related quality of life in premenopausal women with endometriosis-associated pain [Internet]. Journal of endometriosis and pelvic pain disorders. 2019 ; 11( 4): 171-180.[citado 2024 ago. 20 ] Available from: https://doi.org/10.1177/2284026519872401Vancouver
Leyland N, Taylor HS, Archer DF, Peloso PM, Soliman AM, Palac HL, Martinez M, Abrao MS. Elagolix reduced dyspareunia and improved health-related quality of life in premenopausal women with endometriosis-associated pain [Internet]. Journal of endometriosis and pelvic pain disorders. 2019 ; 11( 4): 171-180.[citado 2024 ago. 20 ] Available from: https://doi.org/10.1177/2284026519872401